ArticleBMC gastroenterology2001
Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study.
Article in BMC gastroenterology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 32 citations in OpenAlex.
- A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.Naunyn-Schmiedeberg's archives of pharmacology · 2018Trial
- The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study.Hepatitis monthly · 2013Article
- Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response.PloS one · 2012Article
- A perspective on modelling hepatitis C virus infection.Journal of viral hepatitis · 2010Review
- Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.Critical reviews in immunology · 2010Review
- Modeling HCV kinetics under therapy using PK and PD information.Expert opinion on drug metabolism & toxicology · 2009Review
- ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS.SIAM journal on applied mathematics · 2009Article
- Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.Journal of viral hepatitis · 2008Article
- Hepatitis C Viral Kinetics in Special Populations.Current hepatitis reports · 2008Article
- Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.Journal of theoretical biology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh dose interferon induction treatment of hepatitis C viral infection blocks viral production over 95%. Since dose reduction is often performed due to clinical considerations, the effect of dose reduction on hepatitis C virus kinetics was studied.
methodsA new model that allowed longitudinal changes in the parameters of viral dynamics was used in a group of genotype-1 patients (N = 15) with dose reduction from 10 to 3 million units of interferon daily in combination with ribavirin, in comparison to a control group (N = 9) with no dose reduction.
resultsDose reduction gave rise to a complex viral kinetic pattern, which could be only explained by a decrease in interferon effectiveness in blocking virion production. The benefit of the rapid initial viral decline following the high induction dose is lost after dose reduction. In addition, in some patients also the second phase viral decline slope, which is highly predictive of success of treatment, was impaired by the dose reduction resulting in smaller percentage of viral clearance in the dose reduction group.
conclusionsThese findings, while explaining the failure of many induction schedules, suggest that for genotype-1 patients induction therapy should be continued till HCVRNA negativity in serum in order to increase the sustained response rate for chronic hepatitis C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.